



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/070,209	07/12/2002	Masahiro Sakanaka	57094 (71526)	9390
21874	7590	08/26/2004	EXAMINER	
EDWARDS & ANGELL, LLP			LEITH, PATRICIA A	
P.O. BOX 55874			ART UNIT	
BOSTON, MA 02205			PAPER NUMBER	

1654

DATE MAILED: 08/26/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/070,209

Applicant(s)

SAKANAKA ET AL.

Examiner

Patricia Leith

Art Unit

1654

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 08 June 2004.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 94 and 108-120 is/are pending in the application.
- 4a) Of the above claim(s) 110-114 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 94, 108, 109 and 115-120 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date 6/25/04.
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____.

DETAILED ACTION

Claims 94 and 108-120 are pending in the application.

Election/Restrictions

Applicant's election of nerve cells and cerebral infarction in the reply filed on 6/8/04 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

Because claims 110-114 are directed solely to the non-elected species, these claims are hereby withdrawn from the merits as being drawn to a non-elected invention.

Claims 94, 108-109 and 115-120 were examined on the merits.

Claim Rejections - 35 USC § 102

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claim 94 is rejected under 35 U.S.C. 102(b) as being anticipated by Sananaka et al. (1995) or Masahiro, H (1995), Zhang et al. (1995) or Tamiko et al (1994).

Sananaka et al. (1995) disclosed red ginseng powder containing ginseng saponins and the ginsenoside Rb1 prevented "ischemia-induced learning disability and rescued ischemic hippocampus CA1 neurons in gerbils (see English Abstract).

Masahiro, H (1995) taught that red ginseng administered to *Meriones unguiculatus* (gerbil) prior to inducing ischemia prevented ischemic nerve cell death leading to cerebral infarction (see English Abstract).

Tamiko et al. (1994) administered red ginseng to diabetic patients who were at risk for cerebral infarction (see English Abstract). Because the red ginseng was administered to patients 'susceptible' to cerebral infarction, Tamiko et al. anticipated the claimed invention.

Zhang et al. (1995) disclosed that ginsenosides such as Rb1 from *Panax ginseng* protected rat brains from cerebral infarction (p.44 and pp. 46-48).

Thus, the references demonstrate that red ginseng was well known in the art for positively affecting the outcome of cerebral infarction by inhibiting ischemic

Art Unit: 1654

cell death. It is also clear from Sananaka et al. (1995) as well as Tamiko et al. that ginseng saponins and Rb1 ginsenoside are each inherent to red ginseng powder. Thus, all the references anticipate the claimed invention.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 94, 108-109 and 115-120 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sananaka et al. (1995) or Masahiro, H (1995) or Zhang et al. (1995) or Tamiko et al (1994).

The teachings of Sananaka et al. (1995), Masahiro, H (1995), Zhang et al. (1995) and Tamiko et al (1994) were discussed *supra*. None of the references specifically disclosed the dosage amounts as recited in claims 115-120.

It has been held that where the general conditions of a claim are disclosed in the prior art, discovering the optimum or workable ranges involves only routine skill in the art. *In re Aller*, 220 F2d 454,456,105 USPQ 233; 235 (CCPA 1955).

Art Unit: 1654

see MPEP § 2144.05 part II A. Variance of dosage amounts with regard to known pharmaceutically active ingredients was well known in the art. One of ordinary skill in the art would have been motivated modify the dosage amounts of red ginseng in order to enable the treatment protocol to be matched with the demands and needs of individuals who needed treatment. Such variations is considered optimization of result effective variables, conventional practice in the art of pharmacology.

It would have been obvious to one of ordinary skill in the art at the time Applicants' invention was made to determine all operable and optimal concentrations of components because concentration is an art-recognized result-effective variable which would have been routinely determined and optimized in the pharmaceutical art. Although the prior art do not teach all the various permutations of dosage amounts as Instantly claimed, it would be conventional and within the skill of the art to identify the optional concentrations of red ginseng for treating cerebral ischemia, because it was already known in the art that red ginseng was effective in lessening the effects of the cerebral ischemic condition.

From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, as

evidenced by the references, especially in the absence of evidence to the contrary.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Patricia Leith whose telephone number is (571) 272-0968. The examiner can normally be reached on 8:30am-5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached on (571) 272-0974. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Patricia Leith
Primary Examiner
Art Unit 1654

08/20/04

A handwritten signature in black ink, appearing to read "Patricia Leith", written in a cursive style.